Indefinite graft survival was obtained with murine cardiac allografts using the combined administration of monoclonal antibodies (mAbs) directed against the receptor ligand pair CD2-CD48. Although each antibody could prolong graft survival when given alone, neither resulted in the indefinite graft survival seen with the combination. Combined mAb administration is associated with inhibition of T cell priming and help and subsequent cytotoxic T lymphocyte generation. This indicates that the interaction between CD2 and its ligand is important for antigen priming and recognition, and combined mAbs may prove to be a useful therapeutic regimen for transplantation.
Anti-CD2 receptor and anti-CD2 ligand (CD48) antibodies synergize to prolong allograft survival.
L Qin, K D Chavin, J Lin, H Yagita, J S Bromberg; Anti-CD2 receptor and anti-CD2 ligand (CD48) antibodies synergize to prolong allograft survival.. J Exp Med 1 January 1994; 179 (1): 341–346. doi: https://doi.org/10.1084/jem.179.1.341
Download citation file: